Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib + Vinorelbine in Solid Tumors and Metastatic Breast Cancer
NCT00706030Phase 2Completed
- Sponsor
- Puma Biotechnology, Inc.
- Start
- Apr 2008
- Primary completion
- Oct 2009
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 11
01
Overview
Phase 2, open-label trial of neratinib in solid tumor and breast cancer (4 arms), sponsored by Puma Biotechnology, Inc. Primary endpoints: Overall Response Rate up to 4.5 years and Maximum Tolerated Dose. Started Apr 2008; status: completed.
02
Drugs
neratinib
03
Conditions
solid tumorbreast cancer
Beyond the preview
Go deeper on NCT00706030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00706030.